Nintendo expects profit to fall by 29% this fiscal year and switch sales to 21 million units
Nintendo said on Tuesday that it expects net profit to fall by 29% this fiscal year because it expects sales of switch game consoles and software copies to fall. The company said it expected net profit for the fiscal year starting in April to drop to 340 billion yen ($2.61 billion), compared with 477.69 billion yen in the previous fiscal year. Nintendo said it expected to sell 21 million switch consoles this fiscal year, up from 23.1 million in the previous fiscal year. The company expects to sell 210 million copies of switch software this fiscal year, compared with 235.1 million in the previous fiscal year.
This text is a result of machine translation.
Related companies：
In-depth
Healthcare
China's First Oral COVID-19 Antiviral Medicine in Dispute
An obscure Chinese company called Genuine Biotech(Chinese: 真实生物) was suddenly put under the spotlight on July 25 when the Chinese authority announced the conditional approval of the company's application for adding the treatment of COVID-19 as a new indication of Azvudine under the special review and approval procedures for drug registration.
Aug 08, 2022 09:00 AM
Briefing May 24, 2022 02:24 PM
· Healthcare
Zelensky called on the international community to provide funds for Ukraine's reconstruction, which is expected to cost $500 billion
May 11, 2023 05:07 PM
Nov 16, 2022 05:19 PM
Nov 07, 2022 04:27 PM
Aug 29, 2022 05:45 PM
Briefing May 21, 2022 06:44 AM
· Financials
913 companies have been investigated by public funds since the second quarter, and the six top flow fund managers focus on the leaders of subdivided industries
Healthcare, Technology
Pharmaceutical Machine Vision Company aocheng Nets Tens of Millions in Round A
EqualOcean has learned that aocheng (Chinese: 奥乘智能), a machine vision inspection company in the pharmaceutical field, has recently closed tens of millions of CNY in round A financing.
Sep 18, 2023 11:55 AM
Healthcare
Junshi Biosciences Receives NMPA Approval of sNDA for Toripalimab
The study data showed that compared to chemotherapy alone, toripalimab in combination with chemotherapy in the first-line treatment of patients with advanced NSCLC without EGFR/ALK mutations could significantly improve the PFS and the OS of patients with a manageable safety profile regardless of PD-L1 expression status.
Sep 20, 2022 03:35 PM
Briefing Apr 18, 2022 10:18 PM
· Technology
A number of enterprises on the science and innovation board are listed on the "white list" of key enterprises for operation guarantee and transfer
See more
Read next
Insight
In-depth
Insight
In-depth
Consumer Staples, Communication
An Entrepreneur and Her New Journey to Globalization
Sep 21, 2023 05:40 PM
Insight
In-depth
Industrials · Analysis
EqualOcean｜China's Top 20 ESG Performers Among Private Enterprises（Part I）
Sep 21, 2023 04:43 PM
Insight
In-depth